Motilal Oswal's research report on Divis Labs
The cost pressures are easing across major factors, indicating improved profitability going forward. The outlook for contrast media segment remains encouraging, given DIVI’s capability to have better Iodine recovery and limited investment by formulators to manufacture API. The green-field capital expenditure at Kakinada would not only cater to the company’s growth requirements from FY25 onwards, but also, would reduce the concentration of DIVI business at Hyderabad/Vizag. While the improvement in outlook is encouraging, the valuations remain high, considering the flat earnings growth in FY24 (43x FY24E earnings/33x FY25E earnings). We have a Neutral rating on the stock.
Outlook
We value DIVI at 30x 12M forward earnings to arrive at a price target of INR2,620. We have a Neutral rating on the stock.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.